NEW YORK (GenomeWeb News) – Expression Pathology said today that Roche will use its Liquid Tissue - SRM technology to identify molecular markers as part of its oncology drug programs.
The Rockville, Md.-based company said that it will provide Roche with multiplexed quantitative assays of cancer signaling pathway proteins and support their activation in formalin-fixed, paraffin-embedded samples for mass spectrometry analysis.
“This new approach to tissue analysis has the potential to dramatically streamline and improve biomarker identification in FFPE samples during clinical development,” said Miro Venturi, senior biomarker and experimental medicine leader at Roche, in a statement.
Over the long term, Roche may use the Expression Pathology platform as "a new way of profiling tumors at the molecular level to improve patient stratification and therefore to advance our discovery of personalized medicines," Venturi added.
Financial terms of the agreement were not released.